Recent data suggest the therapeutic benefits following a single administration of Cytori Therapeutics (NASDAQ:CYTX) ADRCs can persist for at least one year in patients with scleroderma-associated impaired hand function (SAIHF). Pivotal studies in SAIHF and urinary incontinence are underway.
Scleradec-I Therapy Benefit Sustained At 12 months
12-month follow-up data from the open-label Scleradec-I study assessing a single administration of Cytori Cell Therapy (ECCS-50) in 12 patients with SAIHF were recently published in Rheumatology. Hand function, as measured through the Cochin, and quality of life, determined using the Scleroderma Health Activity Questionnaire, improved from baseline by 51.3% and 46.8%, respectively, at 12 months (p≤0.001 for both). The Visual Analogue Scale for hand pain also showed a reduction vs baseline, nearing significance (p=0.052). This builds on previously reported six-month data showing improvements across multiple indicators.